High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: A 1H MRS study

American Journal of Psychiatry

Volumn 156, Issue 12, 1999, Pages 1879-1886

  Huang, Wei ^a   Alexander, Gene E ^b   Daly, Eileen M ^b   Shetty, H Umesha ^b   Krasuski, Jack S ^b   Rapoport, Stanley I ^b   Schapiro, Mark B ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INOSITOL; N ACETYLASPARTIC ACID;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN SYNDROME; FEMALE; GENE DOSAGE; HUMAN; MALE; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL;

ADULT; AGE FACTORS; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; BRAIN CHEMISTRY; DIAGNOSIS, DIFFERENTIAL; DOWN SYNDROME; FEMALE; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED;

EID: 0032743882     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Haxby JV, Schapiro MB: Longitudinal study of neuropsychological function in older adults with Down syndrome, in Down Syndrome and Alzheimer Disease. Edited by Epstein C, Nadel L. New York, Wiley-Liss, 1992, pp 35-50
2. Alexander GE, Saunders AM, Szczepanik J, Strassburger T, Pietrini R Dani A, Furey ML, Mentis MJ, Roses AD, Rapoport SI, Schapiro MB: Relation of age and apolipoprotein E to cognitive function in Down syndrome adults. Neuroreport 1997; 8: 1835-1840
3. Lai F, Williams RS: A prospective study of Alzheimer's disease in Down syndrome. Arch Neurol 1989; 46:849-853
4. Schapiro MB, Haxby JV, Grady CL: Nature of mental retardation and dementia in Down syndrome: study with PET, CT and neuropsychology. Neurobiol Aging 1992; 13:723-734
5. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertolini S, Mann DMA, Tabaton M, Gambetti P: Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 1996; 2:93-95
6. Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH: Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome: quantitative regional analysis and comparison with Alzheimer's disease. Arch Neurol 1995; 52:379-391
7. Mann DMA, Yates PO, Marcyniuk B: Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age-related continuum of pathological changes. Neuropathol Appl Neurobiol 1984; 10:185-207
8. Burger PC, Vogel FS: The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. Am J Pathol 1973; 73:457-476
9. Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G1 Martins R, Hockey A, Montgomery P, Beyreuther K, Masters CL: Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 1989; 320:1446-1452
10. Dani A, Pietrini P, Furey M, McIntosh AR, Grady CL, Horwitz B, Freo U, Alexander GE, Schapiro MB: Brain metabolism and cognition in Down syndrome adults associated with development of dementia. Neuroreport 1996; 7:2933-2936
11. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988; 334: 661-665
12. Berridge MJ, Irvine RF: Inositol phosphates and cell signalling. Nature 1989; 341:197-205
13. Garcia-Perez A, Burg MB: Renal medullary organic osmolytes. Physiol Rev 1991; 71:1081-1115
14. Gullans SR, Verbalis JG: Controls of brain volume during hyperosmolar and hypoosmolar conditions. Annu Rev Med 1993; 44:289-301
15. Moats RA, Ernst T, Shonk TK, Ross BD: Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994; 32:110-115
16. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD: Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995; 195:65-72
17. Ernst T, Chang L, Melchor R, Mehringer CM: Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997; 203:829-636
18. Parnetti L, Tarducci R, Presciutti O, Lowenthal DT, Pippi M, Palumbo B, Gobbi G, Pelliccioli GP, Senin U: Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev 1997; 97:9-14
19. Shetty HU, Holloway HW, Schapiro MB: Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease. Clin Chem 1996; 42:298-302
20. Stokes CE, Hawthorne JN: Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. J Neurochem 1987; 48:1018-1021
21. Shetty HU, Schapiro MB, Holloway HW, Rapoport SI: Polyol profiles in Down syndrome: myo-inositol, specifically, is elevated in the cerebrospinal fluid. J Clin Invest 1995; 95:542-546
22. 1H NMR studies of human brain metabolism and physiology, in NMR in Physiology and Biomedicine. Edited by Gillies RJ. New York, Academic Press, 1994, pp 353-372
23. 1H MRS studies in vivo. Neuroreport 1996; 7:1397-1400
24. Shonk T, Ross BD: Role of increased cerebral myo-inositol in the dementia of Down syndrome. Magn Reson Med 1995; 33: 858-861
25. Murata T, Koshino Y, Omori M, Murata I, Nishio M, Horie T, Umezawa Y, Isaki K, Kimura H, Itoh S, Maeda M, Ishii Y: In vivo proton magnetic resonance spectroscopy study on premature aging in adult Down's syndrome. Biol Psychiatry 1993; 34:290-297
26. Schapiro MB, Haxby JV, Grady CL, Duara R, Schlageter NL, White B, Moore A, Sundaram M, Larson SM, Rapoport SI: Decline in cerebral glucose utilization and cognitive function with aging in Down syndrome. J Neurol Neurosurg Psychiatry 1987; 50:766-774
27. Rapoport SI: Anatomic and functional brain imaging in Alzheimer's disease, in Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer D. New York, Raven Press, 1994, pp 1401-1415
28. Talairach J, Tournoux P: Co-Planar Stereotaxic Atlas of the Human Brain. New York, Thieme Medical, 1988
29. Narayana PA, Fotedar LK, Jackson EF, Bohan TP, Butler IJ, Wolinsky JS: Regional in vivo proton magnetic resonance spectroscopy of brain. J Magn Reson 1989; 83:44-52
30. DeCarli C, Maisog J, Murphy DGM, Teichberg D, Rapoport SI, Horwitz B: Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images. J Comput Assist Tomogr 1992; 16:274-284
31. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R: Localized proton NMR spectroscopy in different regions of the human brain in vivo: relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989; 11:47-63
32. 1H spectroscopy in human brain at 4 Tesla. Magn Reson Med 1995; 33:246-252
33. +/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21. Genomics 1995; 25:507-513
34. Acevedo LD, Holloway HW, Rapoport SI, Shetty HU: Increased uptake of myo-inositol in cortical neurons from trisomy 16 mouse. J Mass Spectrom 1997; 32:395-400
35. Fruen BR, Lester BR: Down's syndrome fibroblasts exhibit enhanced inositol uptake. Biochem J 1990; 270:119-123
36. Glanville NT, Byers DM, Cook HW, Spence MW, Palmer FBS: Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. Biochim Biophys Acta 1989; 1004:169-179
37. Urenjak J, Williams SR, Gadian DG, Noble M: Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993; 13:981-989
38. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ: Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci USA 1992; 89:1671-1675
39. 3H]inositol 1,4,5-triphosphate binding in Alzheimer's disease. Neurosci Lett 1988; 94:198-202
40. Klein J, Gonzalez R, Koppen A, Loffelholz K: Free choline and choline metabolites in rat brain and body fluids: sensitive determination and implications for choline supply to the brain. Neurochem Int 1993; 22:293-300
41. Schapiro MB, Atack JR, Hanin I, May C, Haxby JV, Rapoport SI: Lumbar cerebrospinal fluid choline in healthy aging and in Down's syndrome. Arch Neurol 1990; 47:977-980
42. Cohen BM, Renshaw PF, Stoll AL, Wurtman RJ, YurgelunTodd D, Babb SM: Decreased brain choline uptake in older adults: an in vivo proton magnetic resonance spectroscopy study. JAMA 1995; 274:902-907
43. Lott IT, Lai FL: Dementia in Down's syndrome: observations from a neurology clinic. Appl Res Ment Retard 1982; 3:233-239
44. Schapiro MB, Creasey H, Schwarte M, Haxby JV, White B, Moore A, Rapoport SI: Quantitative CT analysis of brain in adult Down's syndrome at different ages. Neurology 1987; 37: 1424-1427
45. Dalton AJ, Crapper DR: Down's syndrome and aging of the brain, in Research to Practice in Mental Retardation. Edited by Mittler P. Baltimore, University Park Press, 1977, pp 391-400
46. Schapiro MB, Rapoport SI: Aging and brain weight in Down's syndrome (letter). Neurology 1989; 39:1407-1408
47. Raz N, Torres IJ, Briggs SD, Spencer WD, Thornton AE, Loken WJ, Gunning FM, McQuain JD, Driesen NR, Acker JD: Selective neuroanatomic abnormalities in Down's syndrome and their cognitive correlates: evidence from MRI morphometry. Neurology 1995; 45:356-366
48. Schuft N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, Jagust W, Kramer JH, Mastrianni JA, Fein G, Weiner MW: Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease: a proton MR spectroscopic imaging and MRI study. Neurology 1997; 49:1513-1521
49. Soher BJ, Van Zijl PCM, Duyn JH, Barker PB: Quantitative proton MR spectroscopic imaging of the human brain. Magn Reson Med 1996; 35:356-363
50. Stokes CE, Gillon KRW, Hawthorne JN: Free and total lipid myo-inositol concentrations decrease with age in human brain. Biochim Biophys Acta 1983; 753:136-138